Prenetics IM8 CEO and CFO bought $1 million of shares in the open market after second quarter results. Insider purchases of this size signal executive confidence and can moderately lift near-term investor sentiment.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | 2 | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2016 | 10.50 |
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 61.71 | 52.25 | 32.13 | 59.05 |
| Receivables | 4.20 | 5.25 | 2.98 | 5.13 |
| Inventory | 3.13 | 6.57 | 7.03 | 13.99 |
| Other | 16.32 | 18.54 | 43.05 | 69.51 |
| 93.66 | 86.15 | 85.20 | 147.68 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.67 | 3.67 | 3.14 | 1.03 |
| ST’ Debt | — | — | — | — |
| Other | 6.11 | 6.49 | 3.09 | 4.14 |
| 39.48 | 36.55 | 28.71 | 36.56 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 35.95 | 46.49 | — | — |
—
|
| ’25 | 8.28 | 11.96 | 23.56 | 48.60 |
92.39
|
| ’24 | 6.41 | 2.54 | 3.53 | 3.45 |
15.94
|
| ’23 | 4.92 | 6.51 | 4.88 | 5.43 |
21.74
|
| ’22 | 92.04 | 4.18 | 4.30 | (87.36) |
13.16
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (12.12) | (15.79) | — | — |
—
|
| ’25 | (3.98) | (5.28) | — | (21.83) |
(21.83)
|
| ’24 | — | — | — | (28.87) |
(28.87)
|
| ’23 | — | — | — | (13.76) |
(13.76)
|
| ’22 | (0.10) | — | — | 14.51 |
14.51
|
| ’21 | — | (1.17) | (0.07) | (0.13) |
(1.37)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (12.12) | 25.54 | — | — |
—
|
| ’25 | (3.98) | (25.27) | — | (76.38) |
(76.38)
|
| ’24 | — | — | — | (29.90) |
(29.90)
|
| ’23 | — | — | — | (14.58) |
(14.58)
|
| ’22 | (0.10) | — | — | 8.22 |
8.22
|
| ’21 | — | (1.17) | (0.07) | (0.13) |
(1.37)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.36) | (0.52) | — | — |
—
|
| ’25 | (0.80) | (0.94) | (0.53) | (1.75) |
(4.15)
|
| ’24 | (0.70) | (0.88) | (0.84) | — |
(3.71)
|
| ’23 | (1.05) | (2.10) | (0.08) | (1.57) |
(5.58)
|
| ’22 | (33.13) | (43.63) | (3.15) | 0.15 |
(37.48)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 18.60 | 3.84 | 2.85 | 3.10 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 131.25 | 46.05 | 7.84 | 18.48 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | 320 | 285 | 98 | — | — | — |
Employees
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.07 | 0.06 | 0.94 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | ‡‡‡‡‡ | 13.16 | 21.74 | 15.94 | 92.39 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | ‡‡‡‡‡ | 27.49% | 40.61% | 58.21% | 52.81% | — | — | — |
Gross Margin
|
| — | — | — | — | — | ‡‡‡‡‡ | (225.82) | (56.67) | (46.02) | (36.21) | — | — | — |
EBT
|
| — | — | — | — | — | ‡‡‡ | (1,715.46%) | (260.63%) | (288.81%) | (39.20%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | — | — | ‡‡‡‡‡ | (190.45) | (64.78) | (49.81) | (39.98) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | — | ‡‡‡‡‡ | 7.54 | 7.79 | 5.93 | 3.78 | — | — | — |
Depreciation
|
| — | — | — | — | — | ‡‡‡ | 2.60 | 1.93 | 1.28 | 6.57 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | (37.48) | (5.58) | (3.71) | (4.15) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ |
Earnings/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 2.86 | (1.22) | (2.31) | (1.55) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | — | ‡‡‡ | (1.24) | (0.07) | (0.08) | (3.88) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 1.62 | (1.30) | (2.39) | (5.44) | — | — | — |
Free CF/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 48.03 | 18.69 | 13.71 | 11.13 | — | — | — |
Book Value/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 5.07 | 11.25 | 12.50 | 14.05 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| — | — | — | — | — | ‡‡‡ | 10.69 | 2.91 | 4.55 | 2.40 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | ‡‡‡ | 0.58 | 0.30 | 0.42 | 1.42 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | ‡‡‡ | (1.46) | 0.31 | 1.60 | 2.10 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | ‡‡‡ | (1.36) | 13.02 | (0.90) | (1.43) | — | — | — |
EV/FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | 14.51 | (13.76) | (28.87) | (21.83) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | ‡‡‡‡‡ | (6.29) | (0.81) | (1.02) | (54.55) | — | — | — |
Capex
|
| — | — | — | — | — | ‡‡‡‡‡ | 8.22 | (14.58) | (29.90) | (76.38) | — | — | — |
FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | 184.62 | 54.18 | 49.60 | 56.48 | — | — | — |
Working Cap'
|
| — | — | — | — | — | ‡‡‡‡‡ | 6.65 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | (159.93) | (61.71) | (52.25) | (32.13) | — | — | — |
Net Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | 243.46 | 210.16 | 171.35 | 156.37 | — | — | — |
Sh' Equity
|
| — | — | — | — | — | ‡‡‡‡‡ | (58.39%) | (22.15%) | (19.80%) | (17.97%) | — | — | — |
ROA
|
| — | — | — | — | — | ‡‡‡ | (49.40%) | (21.85%) | (19.03%) | (22.38%) | — | — | — |
ROIC
|
| — | — | — | — | — | ‡‡‡‡‡ | (176.01%) | (27.65%) | (24.27%) | (23.01%) | — | — | — |
ROE
|
Prenetics Global Limited (PRE), once a SPAC darling riding the COVID testing boom to $276 million in 2021 revenue, has suffered a brutal post-pandemic collapse, with sales plunging 95% to $13 million in 2022 and only tepidly recovering to $30 million in 2024. The stock cratered 97% from $130+ highs to near $3 lows, now in a fragile rebound, yet analysts unanimously target 41% upside—a consensus the contrarian author views as suspect groupthink amid ongoing losses, negative free cash flow, and balance sheet erosion from dilution and debt echoes.
While gross margins have impressively expanded to 50% through pivots into consumer genetics like circleDNA in Asia, and employee productivity doubled, profitability remains elusive: 2024 net losses hit $50 million, ROE lingers at -24%, and forecasts bizarrely project revenue shrinking to near-zero by 2027 despite tiny EPS positives. No insider buying during the recovery raises red flags, contrasting with deleveraging successes and ventures into AI diagnostics and Middle East markets.
This faded SPAC saga pits Wall Street optimism against stark risks—execution fumbles, competition, and macro biotech chills—potentially dooming PRE to further downside or speculative lottery status rather than rebirth.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.